Your SlideShare is downloading. ×
For more than 5 years, the International Market Analysis Research and Consulting Group hasbeen a leading advisor on manage...
&                                      (               (                                                                  ...
&       * +(                             ,               &         *  •       !  •       1  •       1  •       !    "     ...
+                                                             !"            #                  $ %                      " ...
()*+ (*,- ! "" # ""$%                ./0*+1+12* ,-340*                  5(* .6 *7 87*(3                  .(+6.81. .6 *7 87...
&                ()*+ .(*43+3 ! " "# "           %                    &        /       &        -     0                   ...
.Figure 2:1: The impact of Diabetes in the Human Body .......................................................................
Figure 6:7: India: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %), .............. 47Figure 6:8...
.          +Table 2-1: Diagnosis of Diabetes ................................................................................
Table 6-31: India DPP-IV Inhibitors, Sales of Key Players (in 000’ US$), ....................................................
Prices and Order Information  Electronic Access         Electronic Access           CD-ROM Mail Delivery    Hard Copy Mail...
Indian Diabetes Market Report nad Forecast
Upcoming SlideShare
Loading in...5
×

Indian Diabetes Market Report nad Forecast

747

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
747
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
55
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Indian Diabetes Market Report nad Forecast"

  1. 1. For more than 5 years, the International Market Analysis Research and Consulting Group hasbeen a leading advisor on management strategy and market research worldwide. We partnerwith clients in all sectors and regions to identify their highest-value opportunities, address theirmost critical challenges, and transform their businesses.IMARCs information products include major market, scientific, economic and technologicaldevelopments for business leaders in pharmaceutical, industrial, and high technologyorganizations. Market forecasts and industry analysis for biotechnology, advanced materials,pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processingmethods are at the top of the companys expertise.IMARC’s tailored approach combines unfathomable insight into the dynamics of companies andmarkets with close cooperation at all levels of the client organization. This ensures that ourclients achieve unmatchable competitive advantage, build more proficient organizations, andsecure lasting results.
  2. 2. & ( ( ! " # " $%& # ( #)* + ! " # " , - . /- + 0 #)* + 122" 3 452" # ! " # " 6 7- #)* + 122" 3 0 ,- ! "# " 0$ ! " 8 0 07- 9 + *#4) - $%&: 1 + 0 ( ( • # $%& . 0 • ! " # " $%& / 7 9 0 $%3 0 - • $%38 4 0 42 ;4 < = ! " # " 0 $%& • #)* + 1 ! " # " + 0 % + 122" 3 452" # • 9 $%& , # 8 0 7 - • % # 8 5 ; 4 = 0 0 • 9 + :, 0 / # 7- !"#"$!"#%
  3. 3. & * +( , & * • ! • 1 • 1 • ! " # " 4 > . % 0 # "4 0 122" 3 452" # 4 # ! " # " • - , . & * +( & & , * • " 0 • " 0 ! " # " • " 0 ! " • " 0 0 ! " • " 0 • " 0 0/ 01 2 ( • > 8 ? • ? • 0 ? • > ? • > ! " ? • > ? • 0 0 0 ? • + 0 ? • + + 0 ? • 0 + 0 ? • ? ) !"#"$!"#%
  4. 4. + !" # $ % " # & " # ( ) " ! "" # ""$% & ! "" # ""$% & ! " "# " % ! ! "" # ""$% " ! "" # ""$% " ! " "# " % ! "" # " % * % !"#"$!"#%
  5. 5. ()*+ (*,- ! "" # ""$% ./0*+1+12* ,-340* 5(* .6 *7 87*(3 .(+6.81. .6 *7 87*(3 & ()*+ .(*43+3 ! " "# " % $ + , ()*+ (*,- ! "" # ""$% " ./0*+1+12* ,-340* 5(* .6 *7 87*(3 .(+6.81. .6 *7 87*(3 ()*+ .(*43+3 ! " "# " %" $ - ()*+ (*,- ! "" # ""$% ./0*+1+12* ,-340* 5(* .6 *7 87*(3 .(+6.81. .6 *7 87*(3 ()*+ .(*43+3 ! " "# " % & - . ) - ! ()*+ (*,- ! "" # ""$% $ ./0*+1+12* ,-340* " 5(* .6 *7 87*(3 " .(+6.81. .6 *7 87*(3 ()*+ .(*43+3 ! " "# " % .)( ) - " ()*+ (*,- ! "" # ""$% ./0*+1+12* ,-340* 5(* .6 *7 87*(3 .(+6.81. .6 *7 87*(3 ()*+ .(*43+3 ! " "# " % ()*+ (*,- ! "" # ""$% & ./0*+1+12* ,-340* & 5(* .6 *7 87*(3 & .(+6.81. .6 *7 87*(3 ()*+ .(*43+3 ! " "# " % &" . & , & ()*+ (*,- ! "" # ""$% & & ./0*+1+12* ,-340* & & 5(* .6 *7 87*(3 & & .(+6.81. .6 *7 87*(3 & 3 !"#"$!"#%
  6. 6. & ()*+ .(*43+3 ! " "# " % & / & - 0 " ()*+ (*,- ! "" # ""$% & ./0*+1+12* ,-340* & 5(* .6 *7 87*(3 & .(+6.81. .6 *7 87*(3 & ()*+ .(*43+3 ! " "# " % & & ! "" # ""$% && & ! "" # ""$% && & & & " $- #1 /, # #2 / & ! " "# " %" " 9 : ; < 4 !"#"$!"#%
  7. 7. .Figure 2:1: The impact of Diabetes in the Human Body ............................................................................. 14Figure 2:2: Diabetes Complications ............................................................................................................ 20Figure 3:1: Global: Breakup of Patients by Region, (in %) 2010 & 2030.................................................... 21Figure 3:2: India: Tapped and Untapped Diabetes Market, (in Million US$), 2010 .................................... 24Figure 4:1: India: Total Number of Diabetes Patients* (in Million), 2005 & 2010 ....................................... 26Figure 4:2: India: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 &2030 ............................................................................................................................................................ 27Figure 4:3: India: Total Number of Type1 Diabetes Patients* (in Million), 2005 & 2010 ............................ 28Figure 4:4: India: Total Number of Type-1 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030.................................................................................................................................................................... 28Figure 4:5: India: Total Number of Type 2 Diabetes Patients* (in Million), 2005 & 2010 ........................... 29Figure 4:6: India: Total Number of Type-2 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030.................................................................................................................................................................... 29Figure 4:7: India (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010 ............. 30Figure 4:8: India (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015,2020, 2025 & 2030 ...................................................................................................................................... 30Figure 4:9: India: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030 .............. 31Figure 4:10: India (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010.......... 31Figure 4:11: India (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015,2020, 2025 & 2030 ...................................................................................................................................... 32Figure 4:12: India: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030 ......................................... 32Figure 4:13: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)............ 33Figure 4:14: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)............ 33Figure 4:15: India: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030 .............................. 34Figure 4:16: Prevalence of Diabetes across various regions in India ......................................................... 35Figure 4:17: India: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015............... 36Figure 5:1: India: Diabetes Market, (in Million US$), 2005-2009 ................................................................ 37Figure 5:2: India: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %), ...................... 37Figure 5:3: India: Diabetes Market, (in Million US$), 2010-2015 ................................................................ 38Figure 5:4: India: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %), ....... 38Figure 6:1: India: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009 ....................................... 40Figure 6:2: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %), ........... 41Figure 6:3: India: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ........................ 42Figure 6:4: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),........... 43Figure 6:5: India: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015.................................................................................................................................................................... 44Figure 6:6: India: Glitazones Anti-diabetic Sales, (in Million US$), 2005-2009 .......................................... 46 !"#"$!"#%
  8. 8. Figure 6:7: India: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %), .............. 47Figure 6:8: India: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ........................... 49Figure 6:9: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009 ................................................... 50Figure 6:10: India: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),............ 51Figure 6:11: India: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ........................ 54Figure 6:12: India: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009 ................................ 55Figure 6:13: India: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ................. 58Figure 6:14: India: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009 ........... 59Figure 6:15: India: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %), ...... 60Figure 6:16: India: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$), ............... 62Figure 6:17: India: DPP-IV Inhibitors Sales, (in Million US$), 2008 & 2009 ............................................... 64Figure 6:18: India: DPP-IV Inhibitors, Value Market Shares of Key Players (in %), 2008 & 2009 ............. 65Figure 6:19: India: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 .............. 66Figure 6:20: India: Glinides Anti-diabetics Sales, (in Million US$), 2005-2009 .......................................... 67Figure 6:21: India: Glinides Anti-diabetics Market, Value Market Shares of Key Players (in %),............... 68Figure 6:22: India: Glinides Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ........................... 70Figure 6:23: India: Glp-1 Agonist Anti-diabetics Sales, (in 000’ US$), 2008 & 2009 .................................. 71Figure 6:25: India: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 .................. 73Figure 6:26: India: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009 ............................ 73Figure 6:27: India: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players ........... 74Figure 6:28: India: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015 ............. 76Figure 7:1: India: Insulin Sales, (in Million US$), 2005-2009 ...................................................................... 77Figure 7:2: India: Insulin Market, Value Market Shares of Key Molecules (in %), ...................................... 78Figure 7:3: India: Insulin Market, Value Market Shares by Mode of Action (in %), 2009 ........................... 79Figure 7:4: India: Insulin Market, Value Market Shares of Key Players (in %), .......................................... 80Figure 7:5: India: Insulin Sales Forecast, (in Million US$), 2010-2015 ....................................................... 83Figure 8:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets,2010 ............................................................................................................................................................ 84 !"#"$!"#%
  9. 9. . +Table 2-1: Diagnosis of Diabetes ................................................................................................................ 16Table 3-1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030 ............................ 22Table 3-2: Statistics of Top Emerging and Developed Diabetes Markets, 2009 ........................................ 23Table 3-3: Drugs Expected to be launched in the Indian Diabetes Market, 2010-2015 ............................. 25Table 4-1: Prevalence of Type-1 & Type2 Diabetes in India ...................................................................... 27Table 4-2: India: Total Type-2 Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015 ....... 36Table 5-1: India: Contribution of Non-Insulin Anti-diabetics & Insulin towards Total Growth, .................... 39Table 6-1: India: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$), ......................... 41Table 6-2: India: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$), ......................... 43Table 6-3: India: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),........................ 43Table 6-4: India: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$), ........ 44Table 6-5: India: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %), ....... 44Table 6-6: India: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),............................. 46Table 6-7: India: Sun Pharma’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ................................ 47Table 6-8: India: USV’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ............................................. 48Table 6-9: India: Micro lab’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ...................................... 48Table 6-10: India: Piralmal’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ..................................... 48Table 6-11: India: Daichi’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ........................................ 49Table 6-12: India: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009 ....... 51Table 6-13: India: USV’s Biguanide Portfolio Sales (in 000’ US$),............................................................. 52Table 6-14: India: Sun Pharma’s Biguanide Portfolio Sales (in 000’ US$), ................................................ 52Table 6-15: India: Franco Indian’s Biguanide Portfolio Sales (in 000’ US$), .............................................. 53Table 6-16: India: Piralmal’s Biguanide Portfolio Sales (in 000’ US$), ....................................................... 53Table 6-17: India: Panacea Biotech’s Biguanide Portfolio Sales (in 000’ US$),......................................... 53Table 6-18: India: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),................... 56Table 6-19: India: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %), .................. 56Table 6-20: India: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),.................. 57Table 6-21: India: Dr Reddy’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ....................... 57Table 6-22: India: USV’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ............................... 57Table 6-23: India: Serviers’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ........................ 58Table 6-24: India: Piramal’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), .......................... 58Table 6-25: India: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$), ................... 60Table 6-26: India: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), .............................. 61Table 6-27: India: Daiichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$), ........................... 61Table 6-28: India: Sun Pharma’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$), .................. 61Table 6-29: India: Glenmark’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$), ...................... 62Table 6-30: India: Daichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$), ............................ 62 #" !"#"$!"#%
  10. 10. Table 6-31: India DPP-IV Inhibitors, Sales of Key Players (in 000’ US$), .................................................. 64Table 6-32: India: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009 ............................ 65Table 6-33: India: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009 ....................... 65Table 6-34: India: USV’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009 ............................. 66Table 6-35: India: Glinides Anti-diabetics Market, Sales of Key Players (in 000’ US$), ............................. 68Table 6-36: India: Abbot’s Glinides Portfolio Sales (in 000’ US$), 2005-2009 ........................................... 69Table 6-37: India: Torrent’s Glinides Portfolio Sales (in 000’ US$), 2005-2009 ......................................... 69Table 6-38: India: Glenmark’s Glinides Portfolio Sales (in 000’ US$), 2005-2009 ..................................... 69Table 6-39: India: Orchid’s Glinides Portfolio Sales (in 000’ US$), 2005-2009 .......................................... 69Table 6-40: India: Glp-1 Agonist Anti-diabetics Market, Sales of Key Players (in 000’ US$), .................... 71Table 6-41: India: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$) ......................................................... 72Table 6-42: India: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$), .............. 74Table 6-43: India: Piramal’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ...................... 75Table 6-44: India: Fourt’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009 ....... 75Table 6-45: India: Charak Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ......... 75Table 6-46: India: Intas’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009 ....... 75Table 6-47: India: Himalaya’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ................... 76Table 7-1: India: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009 .......................................... 77Table 7-2: India: Insulin Value Shares by Molecule (in %), 2005-2009 ...................................................... 78Table 7-3: India: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009 .................................... 79Table 7-4: India: Insulin Value Shares by Mode of Action (in %), 2005-2009 ............................................ 79Table 7-5: India: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009 ...................................... 80Table 7-6: India: Abott’s/Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$), .......................................... 81Table 7-7: India: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 ................................................... 81Table 7-8: India: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 .................................. 82Table 7-9: India: Biocon’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 .............................................. 82Table 7-10: India: Wockhardt Insulin Portfolio Sales (in 000’ US$), 2005-2009......................................... 82 ## !"#"$!"#%
  11. 11. Prices and Order Information Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery(Single User License) (Multi User License) (Single User License) (Single User License) US$ 800 US$ 2400 US$ 1400 US$ 1400 For more information visit: http://www.imarcgroup.com/indian-diabetes-market-report-and-outlook- 2010-2015/ To buy the complete report or to get a free sample: Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) Email:sales@imarcgroup.com

×